Johnson & Johnson announced a collaborative study with apple to help identify AFib and prevent stroke

January 23, 2019 / Meitong news agency / -- announced that its subsidiary, Janssen Pharmaceutical, will cooperate with Apple company to study and explore the combination of an application of Johnson & Johnson with applewatch's irregular rhythm notification function and ECG monitoring application, and whether it can identify AFib early and improve its treatment effect AFib is the abbreviation of atrial fibrillation, which can lead to stroke and other high-risk complications Currently, about 33 million people around the world are suffering from AFib In the United States alone, about 750000 people are admitted to hospital every year, and about 130000 people lose their lives [i] The purpose of the study was to analyze the effect of applewatch on the early detection and diagnosis of AFib and its potential for stroke prevention This multi-year large-scale research project will be officially launched in the second half of 2019 It is mainly carried out in the United States Practical randomized controlled trials will be conducted for the elderly aged 65 and above The objectives of the study include: to test the results of a heart health program through the irregular rhythm notification function on applewatch; to evaluate the impact of a drug treatment compliance program through an application of Johnson & Johnson "We are very excited about the application of wearable technology in the early diagnosis of stroke," said Paul Stoffels, vice chairman and chief scientific officer of Johnson & Johnson's Executive Committee "Many people with AFib symptoms don't know the risks they face If AFib can be detected, diagnosed and treated as soon as possible, the therapeutic effect will be greatly improved Based on the experience of this research project, in the future, we may be able to detect other diseases in advance through assessable physiological symptoms " "Today, people can learn more about their heart health, including finding symptoms of atrial fibrillation, through applewatch In this way, people can receive treatment in time, or start to consciously cultivate healthy habits to prevent disease " Jeff Williams, chief operating officer of apple, said, "we are very happy to work with Johnson & Johnson, the leading medical player, and we are very happy to see that applewatch can contribute to the promotion of human health." The recent mstops (health screening for stroke prevention) study conducted by Johnson & Johnson showed that early screening can improve the detection rate of AFib "The use of watch based optical heart sensors and electrocardiographic monitoring is a reasonable evolution of this study, which can promote the diagnosis of AFib and improve the clinical results of patients," said Dr Paul Burton, vice president of medical affairs of Johnson & Johnson "This collaboration brings together Johnson & Johnson's expertise and long-term heritage in the treatment of cardiovascular diseases, as well as Apple's experience in using cutting-edge technologies to improve consumer lives Ultimately, we want to improve the treatment of cardiovascular disease and find ways to prevent it " As for Johnson & Johnson, we firmly believe that health is the foundation of a vibrant life, a prosperous community and continuous progress For this reason, over 130 years, we have been committed to promoting the cause of health, so that people at all ages and at all stages of life remain healthy Today, as a global and comprehensive multinational healthcare enterprise, we are committed to using our extensive influence to promote human health and build a better society We strive to improve the accessibility and affordability of medicine, create healthier communities, and enable people around the world to have a healthy body and mind and enjoy a healthy environment We integrate care, science and wisdom to bring profound changes to the development of human health About AFib AFib (atrial fibrillation) is the most common sustained arrhythmia, which can cause blood clots, and then lead to stroke, heart failure and other high-risk complications AFib patients are five times more likely to have a stroke than the general population, and about a third of all stroke patients are caused by AFib [II] As the blood clot in the heart may be very large, apoplexy caused by AFib often damages most areas of the brain, leading to a higher risk of death, leaving more serious sequelae, and later treatment costs According to statistics, about 20% of patients who have experienced a stroke do not know that they have symptoms of AFib [III] About Johnson & Johnson's Janssen Pharmaceutical, Janssen Pharmaceutical is a pharmaceutical subsidiary of Johnson & Johnson At Janssen, we are committed to creating a world free of disease The goal of preventing, blocking, and treating disease in new and better ways has always inspired us We gather advanced ideas and pursue scientific achievements with development prospects We are Xi'an Janssen We join hands with the world to build health.